**5. Perspectives**

In the last decade, the detailed comprehension of the molecular mechanisms involved in psoriasis has led to the development of new biological drugs, such as monoclonal antibodies, recombinant proteins and small RNA drugs, which are currently under evaluation for psoriasis and/or psoriatic arthritis.
